Background Some patients with Zollinger-Ellison syndrome post curative gastrinoma resection continue to show gastric acid hypersecretion; however, the mechanism is unknown. Aim The aim of this study was to prospectively study acid secretion following curative gastrinoma resection and analyze factors contributing in patients with ZollingerEllison syndrome. Methods Fifty patients cured post gastrinoma resection were studied with serial assessments of acid secretory status, cure status and ECL-cell status/activity (with serial biopsies, CgA, urinary N-MIAA). Correlative analysis was performed to determine predictive factors. Results Hypersecretion occurred in 31 patients (62%) and 14 had extreme-hypersecretion. There was an initial decline (3-6 months) in BAO/MAO, which then remained stable for eight years. Preoperative BAO correlated with the postoperative secretion, but not other clinical, tumoral, laboratory variables, the degree of postoperative acid suppression or type of antisecretory drug needed. Hypersecretors had greater postoperative ECL changes (P = 0.005), serum CGA (P = 0.009) and 24-h urinary N-MIAA (P = 0.0038). Conclusions Post curative resection, gastric hypersecretion persists long term (mean 8 years) in 62% of patients and in 28% it is extreme, despite normogastrinemia. No preoperative variable except BAO correlates with postresection hypersecretion. The persistent increased ECL-cell extent post curative resection suggests prolonged hypergastrinemia can lead to changes in ECL-cells that are either irreversible in humans or sustained by unknown mechanisms not involving fasting hypergastrinemia and which can result in hypersecretion, in a proportion of which it can be extreme. Whether similar findings may occur in patients with idiopathic GERD treated for prolonged periods ([10 years) with PPIs, at present, is unknown.
Introduction
Zollinger-Ellison syndrome (ZES) is caused by gastric acid hypersecretion due to the ectopic release of gastrin from a neuroendocrine tumor (i.e., gastrinoma) [1, 2] . Because the diagnosis is often delayed, patients have hypergastrinemia for [4-8 years prior to surgical exploration for cure and many, postoperatively for life, because \40% are cured post resection long term [3] . This prolonged hypergastrinemia not only results in marked increases in acid secretion, it also has profound trophic effects on the gastric mucosal cells causing an increase in parietal cell mass, gastric mucosal thickness and gastric enterochromaffin-like cells (ECL cells) [2, [4] [5] [6] [7] [8] . Therefore, ZES has been proposed to be an excellent natural model to study the chronic effects of hypergastrinemia in humans, as well as a possible natural model to investigate the effects of the rapid reversal of chronic hypergastrinemia, by studying those ZES patients who are successfully, surgically cured [8, 9] .
Both of the above areas are receiving increasing attention because of the increasing number of patients with gastro-esophageal reflux disease (GERD) chronically taking proton pump inhibitors (PPI), with 80-100% developing hypergastrinemia, including a significant percent in a range seen in ZES patients [9] [10] [11] [12] [13] . Whereas numerous studies have shown that such treatment is safe and effective short term (\5 years) [8, 14, 15] , the long-term consequences of such treatment are still largely unknown. The importance of the changes is that ECL-cell hyperplasia can progress to gastric carcinoids [11, 16, 17] , which can occasionally be malignant [18] . The ECL and parietal cell hyperplasia can lead to gastric hypersecretion after stopping antisecretory treatment (rebound hypersecretion) which can make it difficult to wean patients with GERD off of PPIs [11, [19] [20] [21] [22] . A recent study reports even healthy, asymptomatic individuals treated for only an 8-week period with PPIs can develop dyspeptic symptoms when the PPIs are stopped [23] . Whereas the possible development of gastric carcinoid tumors in both animals and humans [4, 5, 8, 11, 24] with chronic long-term gastric antisecretory treatment has been extensively studied; in humans, much less information is available on rebound hypersecretion and there are few long-term studies on the effects of rapid reversal of chronic hypergastrinemia, such as after stopping chronic PPI treatment [11, 19, 20, 22] .
Previous studies show approximately 30-40% of ZES patients are cured long term [3, 25] and, in proportion, mild gastric acid hypersecretion may persist [26] . However, neither the possible mechanisms leading to this latter finding are known or have been studied, nor is it known if similar results might be seen in GERD patients treated for very prolonged periods ([10 years). Studying the gastric acid secretion following curative resection of the gastrinoma could serve as a natural model for acid secretory changes that might occur after withdrawal of prolonged treatment with PPIs and may provide an insight into the mechanisms that are involved. To address these questions we studied gastric acid secretion in 50 ZES patients who underwent curative gastrinoma resection and attempted to define factors that may be associated with gastric acid hypersecretion post curative resection in these patients.
Methods
All patients with ZES referred to the National Institutes of Health were considered for this study. These patients are included in the prospective study of ZES approved by the Clinical Research Committee of the National Institute of Diabetes and Digestive and Kidney Diseases. To be eligible for participation in our study, patients needed to fulfill the following criteria: (1) have an established diagnosis of ZES as previously defined [27] , (2) agree to undergo exploratory laparotomy for possible cure, (3) be eligible for curative surgery as previously defined [3, 25] , (4) have no medical contraindications to surgery, (5) have no medical illness limiting life expectancy, and (6) agree to long-term follow-up including an assessment of disease-free status, gastric acid secretory status and ECL-cell activity.
The diagnosis of ZES was established by a combination of the following criteria as specified previously [2, 25, 27] including: (1) an elevated fasting serum gastrin concentration [13] , (2) gastric acid hypersecretion with a basal acid output (BAO)[15 mEq/h in patients without previous gastric acid-reducing surgery and [5 mEq/h in patients with previous gastric acid-reducing surgery [2] , (3) basal gastric fluid pH of B2 [2] , (4) positive secretin or calcium provocative test result [28] and/or, (5) positive histological confirmation of gastrinoma.
Serum gastrin concentrations were measured by Bioscience Laboratories (New York, NY) until 1994 and subsequently by Mayo Clinic Laboratories (Rochester, MN). Secretin provocation testing was performed as described previously [28] where a positive secretin provocation test result was defined as a C120-pg/ml increase over the pre-injection fasting gastrin concentration [28] .
The calcium provocative test was performed as described previously [28] using calcium gluconate (10%) (54 mg/kg per hour [5 mg calcium/kg per hour]) given by intravenous infusion for 3 h. An increase of C395 pg/ml over the average of the pre-infusion values was considered a positive test [28] .
The extent of ECL-cell hyperplasia was determined from endoscopic biopsies [5, 24, 29] and also assessed quantitatively by determination of fasting chromogranin A (CgA) levels [30] [31] [32] and 24-h urinary N-methylimidazoleacetic acid (N-MIAA) excretion rate [33, 34] . The extent of ECL-cell changes was determined as outlined in the specific protocol section. Serum CgA levels were determined by immunochemilluminometric assay using an amino and carboxyl directed antibody [30, 34] (Quest Diagnostics Nichols Institutes, San Juan Capistrano, CA). The normal range is 1.6-5.6 ng/ml. The intra-assay variation was 11.6% for a normal control (i.e., 4.1 ng/ml) and 8% for a high control (i.e., 12.8 ng/ml). The inter-assay variation was 5.9% for a normal control, 6.7% for the high control, and 6.6% for a very high control (i.e., 100 ng/ml). A 24-h urine was collected while patients were on a histamine-restricted diet and was analyzed for N-MIAA as described previously [34] . The N-MIAA determination was done using quantitative mass spectrometry (Vanderbilt Pathology and Laboratories Services, Nashville, TN). The normal range is 50-230 mcg of N-MIAA/gm of creatinine.
To be evaluated for surgery, all patients underwent tumor localization studies and studies to determine the presence or absence of MEN1. Preoperative tumor localization included conventional imaging studies which performed including transabdominal ultrasonography (US), computerized tomography (CT scan), magnetic resonance imaging (MRI) and selective abdominal angiography in patients in whom the tumor location or extent was unclear after these other conventional imaging studies [3, 25, 35, 36] . Since June 1994 all patients underwent somatostatin receptor scintigraphy (SRS) using 6 mCi of [ 111 In-DTPADPhe 1 ]octreotide with spot views, whole body views and with single photon emission CT imaging at 4-and 24-h post injection [25, 35, 37] . Distant metastasis to the spine was evaluated using 99 M-technetium bone scanning after the injection of 25 mCi of methylene diphosphonate, SRS and spinal MRI [38] . Functional localization of the gastrinoma was also done with patients undergoing either selective transhepatic portal venous gastrin sampling (January 1980 to April 1992) or later selective intra-arterial injection of secretin with hepatic venous gastrin sampling as described previously [35, 39] .
Patients were considered for attempted curative surgery according to previously defined criteria [25, 35, 40] . Surgical exploration was performed on all patients with ZES without MEN1 who did not have diffuse liver metastases or an illness limiting life expectancy. Patients with ZES with MEN1 also underwent exploratory laparotomy if they had an imagable lesion C2 cm and did not have diffuse liver metastases or an associated illness limiting life expectancy, as described previously [35, [41] [42] [43] .
The surgical protocol employed was described previously [25, 35, 40, 42] . Between 1980 and 1987 an extensive search for the gastrinoma was done using palpation, intraoperative ultrasonography with a 10 MHz real time transducer, and an extended Kocher maneuver of the duodenum to examine the pancreatic head area. Intraoperative endoscopic transillumination of the duodenum and a routine duodenotomy have been performed as well since 1987 [25, 35, 44] .
Diagnostic criteria for ZES with Multiple Endocrine Neoplasia-type 1 (MEN1) were as previously described [41, 43, 45] .
Specific Protocol
All eligible surgical patients who met the following criteria were included in this prospective study: (1) their highest postoperative BAO was measured [6 months post resection; (2) the patient underwent yearly follow-up evaluation for disease activity, including acid secretory studies and assessment of tumor location and extent; and (3) the patient had at least 2 years disease-free follow-up from the last postoperative acid secretory studies.
After surgery and prior to discharge from the hospital when the patient was eating and maintained on their standard dose of antisecretory drug, fasting serum gastrin concentrations were determined on at least three separate days. If resection was thought complete, a secretin test was performed [25] [26] [27] 35] . Each patient was discharged on the same dose of oral antisecretory drug that he or she was taking before surgery [25, 35] . Patients were evaluated at 3-6 months after surgery and then yearly as described above with fasting gastrins and detailed imaging studies. If fasting gastrin was normal, then gastric secretory studies and secretin testing were done after withdrawing any antisecretory drugs [25] [26] [27] 35] . Disease-free was defined as a patient having all three of the following at each postoperative follow-up visit: (1) normal fasting serum gastrin concentrations [13] , (2) negative gastrin provocation testing with secretin [28] , and (3) no evidence of tumor on imaging studies [25, 27, 35] .
Upper gastrointestinal endoscopy was performed on all patients at each visit. Any abnormality was biopsied. On at least one occasion eight biopsy specimens (4-greater curvature and 4-lesser curvature) from the gastric body mucosa were taken as described previously [5, 24, 29] . Serial 5-lm thick sections of gastric body mucosa perpendicular to the mucosal surface were stained with H&E Dig Dis Sci (2011) 56:139-154 141 for evaluation of the type of mucosa and immunostained for endocrine cells using a monoclonal antibody against CgA (clone LK2H10; working dilution-1: 250; Biogenex Laboratories, San Ramon, CA). Detection was done using biotinylated anti-mouse immunoglobulin as a secondary antibody and an avidin-biotin-complex-peroxidase technique with diaminobenzidine tetrahydrochloride as a chromogen substrate [5, 24, 29] . Gastric endocrine cell distribution was determined as described previously [5, 24, 29] . The ECL-cell changes were evaluated qualitatively using the histopathologic classification proposed by Solcia et al. [16] according to the criteria previously published [5, 24, 29] . Using these criteria [5, 24, 29] , ECL-cell changes were classified as diffuse hyperplasia (DH), linear hyperplasia (LH), micronodular hyperplasia (MH), adenomatoid hyperplasia (AH), or dysplasia. DH, LH and MH were further subdivided into three grades: mild, moderate, or severe [5, 24, 29] . Carcinoid tumors were diagnosed when the ECL-cell lesions exceeded 0.5 mm in diameter [16] . Patients were classified both according to the highest grade of endocrine cell hyperplasia and by the magnitude of the ECL-cell index [5, 24, 29] , which was the average value for all biopsies using a scoring system as described previously [5, 24, 29, 46] . Presence of H. pylori was assessed on routine biopsies obtained for histology [5, 24, 29] . Postoperative BAO and MAO were measured in patients that were possibly cured as described previously [2, 26, 47] . At each follow-up visit an attempt was made to reduce the antisecretory drug requirement as described previously [26, 48] . Specifically, for patients taking PPIs, the dose was first reduced to the equivalent of omeprazole 20 mg/day, then an H2 receptor antagonist started, which was then attempted to be withdrawn on subsequent visits.
The highest acid secretory rate post resection was used to stratify patients into three groups: normosecretors had the highest recorded BAO \15 mEq/h; moderate hypersecretors, BAO 15-24.9 mEq/h; and extreme hypersecretors, BAO C25 mEq/h. These hypersecretory stratifications were used because [95% of patients without ZES with idiopathic hypersecretion have a BAO\25 mEq/h [49] . With prior acid-reducing surgery (vagotomy and/or partial gastrectomy) the corresponding values were \5 mEq/h, [5-14.9 mEq/h and C15 mEq/h. Patients were also stratified according to the level of acid control postoperatively based on the acid secretory rates as described previously [50] . Specifically, patients were classified as showing drug-induced achlorhydria if all antisecretory drug measurements showed no acid, and as showing drug-induced sustained hypochlorhydria if the gastric acid secretion for the hour prior to the next dose of antisecretory drug was \0.2 mEq/h for [50% of the assessment periods [50] .
Statistical Analysis
Statistical analysis was performed using the Student's t test, the Fisher exact test and ANOVA. For a post hoc test the Bonferroni/Dunn test was used. Values of P \ 0.05 were considered significant. All values are expressed as mean ± standard error of the mean (SEM).
Results
This study included 181 consecutive patients with ZES undergoing surgery for gastrinoma resection at the National Institutes of Health (Fig. 1) . To be eligible for this study patients had to be disease-free post resection, have gastric secretory studies at least 6 months post resection, and have at least 2 years of follow-up from their last evaluation to insure disease-free status. Following surgery and at 3-6 months postoperatively, 53 patients were disease-free. Three of these 53 patients were not included in this study because their follow-up time was less than the required 2 years. Of the 50 patients who fulfilled all the criteria for the study, 44 were disease-free following the first surgery while six were disease-free after the second surgery.
In the 50 patients in the study, there were 19 patients (38%) who became and remained normosecretors on all of Fig. 1 Algorithm of patients studied. Numbers in parentheses refer to the numbers of patients in each category. To be eligible for the study patients had to be cured post resection and have at least a two-year follow-up from their last postoperative BAO. Patients were stratified into three groups based on their highest postoperative acid secretory level. Patients with or without a previous acid-reducing surgery were classified as postoperative normosecretors if the BAO was \5 or 15 mEq/h, respectively; moderate hypersecretors if BAO was 5-14.9 or 15-24.9, respectively; and extreme hypersecretors if BAO was C15 or C25 mEq/h, respectively their postoperative follow-up evaluations and 31 patients (62%) who had hypersecretion on at least one postoperative follow-up visit (Fig. 1 ). For these 31 hypersecretors, 17 patients (34%) (with or without previous acid-reducing surgery) were moderate hypersecretors (BAO 5-14.9 or 15-24.9 mEq/h, respectively), and 14 patients (28%) were extreme hypersecretors (BAO C15 or C25 mEq/h, respectively). The mean postoperative BAO differed significantly (P \ 0.0001) between these three secretory categories (Fig. 2) . In the 41 patients without gastric acidreducing surgery, the highest postoperative BAO for the 17 patients who were normosecretors varied from 0 to 13 with a mean of 8 ± 1 mEq/h (Fig. 2, left panel) . In the 13 patients with moderate hypersecretion without acid-reducing surgery, the highest postoperative BAO varied from 15 to 24 with a mean of 21 ± 1 mEq/h, which was significantly greater (P = 0.0012) than the BAO in normosecretors (Fig. 2 , middle panel). In the extreme hypersecretors, the highest postoperative BAO varied from 26 to 67 with a mean of 37 ± 4 mEq/h, which was significantly greater (P \ 0.0001) than the BAO of the moderate hypersecretors ( Fig. 2 , right panel). The comparable postoperative mean BAOs (ranges) for patients with previous acid-reducing surgery were 1 ± 1 (0.3-1.3 mEq/h, n = 2), 7 ± 1 (5-9 mEq/h, n = 4), and 17 ± 2 (15-20 mEq/h, n = 3) for the normosecretors, moderate, and extreme hypersecretors, respectively.
A comparison of the demographic data and other clinical variables between the patients in the three postoperative secretory groups did not reveal any significant difference in age at surgery, gender, age at ZES onset or diagnosis, duration of disease at surgery, duration from surgery to highest postoperative BAO, duration of disease-free follow-up from diagnosis or frequency of gastric acid-reducing surgery in each secretory group (Table 1) . Diarrhea (82% overall) was the most frequent symptom at diagnosis in all three groups and was present in 15 (79%) normosecretors, 14 (82%) moderate hypersecretors, and 12 (86%) extreme hypersecretors. Other presenting symptoms did not differ in frequency between the three groups ( Table 1 ). The duration from surgery to the highest postoperative BAO varied from 0.5 to 14 with a mean of 4 ± 0.5 years overall and did not differ significantly between normosecretors, moderate hypersecretors and extreme hypersecretors (Fig. 3) .
To determine whether the magnitude of preoperative basal acid secretion correlated with postoperative acid secretory status, the preoperative BAO was compared between the three postoperative acid secretory groups ( Table 2 , Fig. 4 ). The mean preoperative BAO in the extreme hypersecretors varied from 15 to 95 with a mean of 58 ± 7 mEq/h (Fig. 4 , right panel) and was significantly higher (P \ 0.05) than in moderate hypersecretors with a mean of 41 ± 6 (range 7-95) mEq/h (Fig. 4 , middle panel), and in normosecretors (P \ 0.001), whose values varied between 2 and 85 with a mean of 29 ± 5 mEq/h ( Table 2 , Fig. 4, right panel) . Following curative resection, the mean BAO declined in all three secretory groups (Fig. 5 , left panel) with a 75 ± 8, 54 ± 10, and 53 ± 10 percent decrease at the first postoperative evaluation in normosecretors, moderate hypersecretors, and extreme hypersecretors, respectively. The mean BAO at the first postoperative evaluation was higher (P \ 0.001) in extreme hypersecretors (21 ± 3 mEq/h, range 6-47) and moderate hypersecretors (14 ± 2 mEq/h, range 3-36) (P \ 0.01) than in normosecretors (6 ± 1 mEq/h, range 0-19) ( Table 3 , Fig. 5 ). However, after this initial decrease in BAO post curative resection, the mean postoperative BAO remained fairly stable for each secretory group for the next 8 years (Fig. 5, left panel) .
The preoperative MAO was also compared between the three secretory groups. The mean preoperative MAO in the extreme hypersecretors varied from 42 to 136 mEq/h with a mean of 88 ± 8 mEq/h and was higher (P = 0.0003) than in normosecretors with a mean of 44 ± 6 (range 4-121) mEq/h (Table 2, Fig. 6 ). The preoperative MAO in moderate hypersecretors varied from 22 to 127 with a mean of 67 ± 9 mEq/h and was also significantly higher (P = 0.03) than in nomosecretors (Table 2 , Fig. 6 ). Similar to the BAO following curative resection, the MAO also declined in all three acid secretory groups post curative resection (Fig. 5 , right panel), with a 35 ± 9, 19 ± 9 and 29 ± 10% decrease at the first postoperative evaluation in normosecretors, moderate hypersecretors, and extreme hypersecretors, respectively. The mean MAO at the first postoperative evaluation was higher (P \ 0.01) in extreme hypersecretors 64 ± 9 (19-143) mEq/h than in normosecretors 32 ± 6 (0-97) mEq/h ( Table 3 ). The rate of change in the MAO post curative resection was also similar to the post operative BAO time curve (Fig. 5) . Specifically, after the initial decrease in the MAO at the first post operative evaluation following curative resection, the mean MAO remained fairly constant at this level for the next 8 years (Fig. 5 , right panel).
To determine if preoperative fasting gastrin levels and changes in these levels correlated with the magnitude of the postoperative acid secretion, we compared the three acid secretory groups, their preoperative serum gastrin levels, preoperative change in serum gastrin with secretin stimulation (delta secretin), immediate postoperative fasting serum gastrin level, immediate postoperative delta secretin, fasting serum gastrin at the time of the highest BAO and delta secretin at the time of the highest BAO (Tables 2 and  3 ). There were no significant differences in any of these gastrin levels between the three postoperative acid secretory categories (Tables 2 and 3) . The presence or absence of H. pylori and previous antisecretory drug treatment can affect acid secretory rates [51] [52] [53] . Therefore, we compared the effect of both of these variables on postoperative acid secretory rate (Tables 2 and 3 ). All patients were (Table 2) . Overall, 19 patients (38%) were on treatment with a histamine H 2 antagonist while 31 patients (62%) were on treatment with omeprazole at the time of surgery. There were no significant differences between the three acid secretory groups in the type of antisecretory drug (omeprazole or histamine H 2 antagonist), its dosage, or duration of their treatment prior to surgery (Table 2) . Only 10% of patients had H. pylori present and there was no significant difference in its frequency in the three post curative resection acid secretory groups (Table 3) . To provide insight into whether the postoperative longterm use of PPIs could be contributing to the presence of the hypersecretion post curative resection, the type of maintenance antisecretory drug, if any at the time of the highest postoperative BAO, was compared in patients with or without hypersecretion. Long-term (9/50) patients needed no antisecretory drug, 15 required a low dose of H2 blocker, and 26 required omeprazole. There was no significant difference in the percentage of patients maintained or not maintained on PPIs that showed acid hypersecretion during long-term follow-up (65 vs. 59%).
To determine if any tumoral characteristics correlated with the magnitude of postoperative acid secretion, we compared the primary tumor location and size as well as the extent of the tumor at surgery between the three postoperative acid secretory groups (Table 4 ). The duodenum was the most common primary site with 17 patients (34%) having a gastrinoma in this location. Overall, the gastrinoma primary was B1 cm in 22 patients (44%), between 1.1 and 2.9 cm in 17 patients (34%), and [2.9 cm in 11 patients (22%). Thirty-three patients (66%) had a primary tumor only resected and the remainder had a primary tumor with a lymph node found at surgery (Table 4) . There was no significant difference in the location of the primary, size of the primary, or extent of the tumor at surgery between the three acid secretory groups (Table 4) .
To assess whether the need or extent of control of acid secretion postoperatively might correlate with the degree of post curative acid secretion, these variables were correlated (Table 5 ). Post curative resection the antisecretory drug dose needed to control acid secretion could be reduced in all patients, with 18/50 (36%) able to stop all drugs for at least 6 months and 23 (46%) either requiring no drug or only a low dose of H2 receptor antagonist for at least a 6-month period. At last follow-up, 30 patients were taking low doses of omeprazole (median dose 20 QD). Between post curative normosecretors or moderate/extreme hypersecretors, there was no difference in the median postoperative dose of omeprazole used for those who required PPIs, the percentage who had dose reductions or the percentage in which BAO was assessed after at least 6 months of no treatment or a low dose of H2 receptor antagonist (Table 5 ). Furthermore, the average level of control of acid secretion for the hour prior to the next dose of antisecretory drug was similar for each of the three post curative acid secretory groups. Lastly, the percentage of patients showing marked drug-induced acid suppression (complete achlorhydria, or sustained hypochlorhydria) did not differ between the three groups (Table 5) . These results support the conclusion that the postoperative drug dosage, level of acid control or drug used were not contributing to the magnitude of the postoperative acid secretion.
Since the magnitude of the mean preoperative BAO correlated with the postoperative acid secretory status and prediction of postoperative extreme hypersecretion would be clinically important, we attempted to define the likelihood of a given patient having postoperative extreme acid hypersecretion by calculating the sensitivity, specificity, positive predictive and negative predictive value of various preoperative BAO levels in the occurrence of extreme hypersecretion (Table 6) . A preoperative BAO of [30 or [35 mEq/h had excellent sensitivity (i.e., 90-100%) and negative predictive value, but low specificity or positive predictive value (42-53%). A preoperative BAO [45 mEq/h still retained acceptable sensitivity and negative predictive value (i.e., 75-89%), whereas it also had good specificity (78%) but had a low positive predictive value (i.e., 56%) ( Table 6 ).
To determine if differences in the postoperative ECLcell changes correlated with postoperative acid secretory status, we compared the qualitative degree of ECL-cell hyperplasia in patients with or without acid hypersecretion expressed either as the most advanced ECL-cell change seen [5, 6, 24, 29, 54] or the ECL-cell index, a mean numerical value of hyperplasia for all biopsies [5, 24, 46] . We also compared the urinary N-methylimidazole acetic acid (N-MIAA) excretion rate and serum CgA levels in the different groups, both measures of the degree of ECL-cell hyperplasia [30] [31] [32] . Sixteen of the 19 normosecretors had [2 gastric biopsies (median of 8), which allowed reliable assessment of ECL-cell changes. The most advanced ECLcell change was a normal pattern (n = 1), mild (n = 7) or moderate (n = 5) DH, mild LH (n = 1), and mild MH (n = 1). The mean ECL-cell index was 1.16 ± 0.24 with a range from 0 to 3.6. In contrast, for the 29 patients with postoperative hypersecretion with [2 gastric biopsies allowing assessment of postoperative ECL-cell change, the most advanced ECL-cell change was mild (n = 2), moderate (n = 9) or severe (n = 12) DH; mild (n = 3) or moderate (n = 2) LH, and dysplasia (n = 1). The mean ECL-cell index overall for the hypersecretors was 1.90 ± 0.23 with a value of 1.51 ± 0.13 for the moderate hypersecretors and 2.30 ± 0.43 for the extreme hypersecretors. Only 23% (3/16) of the 19 normosecretors had severe DH or a more advanced ECL-cell change which was significantly less (P = 0.005) than the 63% (18/29) seen in hypersecretors. Representative results from four patients are shown in Fig. 7 . The mean ECL-cell index was significantly higher (P = 0.0124) in all hypersecretors than normosecretors (1.90 ± 0.23) vs. (1.16 ± 0.24). The gastric biopsies assessing ECL-cell changes obtained were 7.8 ± 0.91, 7.4 ± 1.1 and 6.3 ± 1.2 years post resection for normosecretors, moderate, and extreme hypersecretors, respectively, which were not significantly different. The mean 24-h urinary N-MIAA excretion varied from 35 to 226 with a mean of 109 ± 11.5 mcg/g creatinine in normosecretors and from 52 to 390 with a mean of 157 ± 17.2 mcg/g creatinine in hypersecretors. There were significantly (P = 0.038) more hypersecretors (11 of 28 patients) with 24-h urinary N-MIAA greater [150mcg/g creatinine Secretory groups are as defined in Table 1 legend Compared to normosecretors: * P \ 0.001, ** P \ 0.03. Compared to moderate hypersecretors: *** P \ 0.05 a Increase in serum gastrin level following secretin injection [28] b This is the last gastric acid antisecretory drug used prior to surgery c Total duration is the total time the patient was treated with any gastric acid antisecretory drug prior to curative resection d Dose of antisecretory drug patient was taking at the time of curative resection. All histamine H 2 -inhibitors were converted to ranitidine equivalents as previously described [26, 73] e Number and percent are as defined in Table 1 legend compared to normosecretors (2 of 18 patients). The mean CGA levels in the hypersecretors varied from 3.4 to 93 with a mean of 18.8 ± 3.8 ng/ml and were significantly higher (P = 0.009) than in normosecretors with a mean of 5.5 ± 0.9 (range 2-15) ng/ml. The mean CGA levels were also significantly higher (P = 0.04) in extreme hypersecretors at 17.5 ± 6.6 (range 3.5-93) ng/ml compared to normosecretors at 5.5 ± 0.9 (range 2-15) ng/ml.
Discussion
This study was undertaken to attempt to provide insights into the mechanism(s) that contribute to some patients with ZES continuing to show prolonged gastric acid hypersecretion after rapid reversal of the chronic hypergastrinemia by curative gastrinoma resection [26] . This study not only is important in the management of ZES patients, but has a potentially wider importance, in that in could serve as a natural model of the effects of the rapid reversal of chronic hypergastrinemia in humans, an area that is currently receiving increased attention. This is occurring because of the widespread use of PPIs in the general population for GERD which results in 80-100% developing hypergastrinemia, including a percent in a range seen in ZES [9] [10] [11] [12] [13] .
The possible consequences of very long-term treatment with PPIs are still uncertain, although those possibly due to the PPI-induced hypochlorhydria/achlorhydria have been extensively studied [4, 7, 11, 55, 56] . Many studies in animals and humans have examined the ability of chronic PPI treatment to cause achlorhydria-induced hypergastrinemia, which can, in turn, cause trophic effects in the gastric mucosa [4, 7, 11, 55, 56] , resulting in gastric carcinoids [4, 11, 55, 56] . The chronic hypergastrinemic effect that has been less well studied, but is receiving increasing Fig. 4 Comparison of preoperative basal acid output (BAO) with postoperative acid secretory category in patients disease-free after resection of gastrinoma. Each symbol represents data from one patient. Closed symbols are from patients without previous gastric acid-reducing surgery (n = 9) and half symbols are from patients with previous acid-reducing surgery (n = 41). Patients were stratified into three different groups based on their highest postoperative acid secretory rate as defined in Fig. 1 legend. The horizontal line represents the mean while the vertical bars on either side represent the SEM for each acid secretory category attention, is its ability to lead to the development of rebound acid hypersecretion when the antisecretory drug is stopped [11, [19] [20] [21] [22] . This can result in the recurrence or worsening of symptoms after withdrawal of gastric antisecretory drug therapy [19, 23, 57, 58] . Studies in animals demonstrate that marked acid inhibition by antisecretory agents can result in up to a 400% increase in BAO and 100% increase in MAO post-treatment [59, 60] . That the drug-induced hypergastrinemia resulting in ECL and parietal cell hyperplasia/hypertrophy is responsible for the rebound hypersecretion following PPI treatment and withdrawal is suggested by the fact that it is abolished by antrectomy and by gastrin receptor blockade [61, 62] . Rebound hypersecretion is generally short-lasting and mild, if present at all, after prolonged treatment with H2 blockers [11, 21] . Recent studies show acid rebound does occur after PPIs and that it is not infrequent, occurring in 62-90% of patients [11, [19] [20] [21] [22] . There is, in general, little known about rebound acid hypersecretion after prolonged gastric antisecretory treatment in humans. Since the induction of hypergastrinemia has been demonstrated to be the underlying mechanism by which PPIs or other potent gastric antisecretory drugs induce ECL-cell hyperplasia and increased parietal cell density [7, 22, 61, 63] , a potential good natural model to study to provide insights in humans to the effect of suddenly ending chronic hypergastrinemia, as occurs when a potent gastric acid anti-suppressant is stopped, is to study patients with ZES post curative gastrinoma resection. Only one study evaluated acid secretion following gastrinoma resection [26] . This study did not investigate the possible mechanisms involved and contained insufficient numbers of patients to allow detailed correlative analysis to provide possible insights into contributing factors. Our study has none of these limitations.
In this study, 62% of our patients continued to have acid hypersecretion post curative resection, of which 28% exceeded levels of hypersecretion seen in[95% of patients with idiopathic hypersecretion [49] (i.e., were extreme hypersecretors [BAO C 25 mEq/h]). In a previous study involving 20 patients with gastrinoma post curative resection [26] , 67% of the patients had continued hypersecretion. However, no patient had extreme hypersecretion. These studies show that acid hypersecretion is frequent in Immediate postop means within two weeks of curative resection. Delta secretin is the increase in serum gastrin following secretin injection [28] e H. pylori status refers to the results of evaluation for the presence of H. pylori as defined in METHODS post curative resection and prior to or at time of highest BAO f Number and percent are as defined in Table 1 legend patients with gastrinoma post curative resection and that high levels of hypersecretion are not infrequent, occurring in over a quarter of the patients cured. The high frequency/ levels of acid hypersecretion were not due to the fact that patients were examined too soon after curative resection or because the patients were not cured. The latter possibility was excluded because all patients remained cured for at least two years after their highest post curative BAO and cure was assessed by both gastrin studies (fasting/secretin provocative testing) and imaging studies, which detect all relapses [13, 27, 28] . Except for the study noted above [26] , there are currently no human studies addressing the acid secretory changes that occur following reversal of prolonged hypergastrinemia of [5 years duration induced by any cause. Weinstein et al. [64] studied the gastric endoscopic and biopsy changes after 2 years of omeprazole treatment in patients with Barrett's esophagus. They found that gastric hypersecretion and parietal cell hyperplasia which occurred during the treatment reverted to normal within 3 months of discontinuation of omeprazole. Fossmark et al. [22] demonstrated that in 7 patients with GERD who had taken PPIs for[1 year and were studied post antireflux surgery after stopping the PPI, the MAO decreased over a 26-week period as well as the serum CGA, serum gastrin and number of gastric HDC positive cells on biopsy. In studies in rats [59, 65, 66] treated with Secretory groups are as defined in Table 1 legend a Location, size and extent of tumor are based on operative findings b Other primary locations include lymph node (n = 22), ovary (n = 1), liver (n = 2), and omentum (n = 1) omeprazole for 16-70 days, ECL and parietal cell hyperplasia developed, withdrawal of omeprazole was followed by a rebound increase in MAO with a gradual return toward control levels by 70 days, with ECL density returning to normal by 100-140 days. At present the mechanism(s) responsible for the persistent hypersecretion post curative gastrinoma resection in our patients are unknown; however, our study provides some possible insights. First, lack of cure of the gastrinoma is unlikely, because all our patients underwent rigorous assessment of cure. Second, the possibility that an unknown non-gastrin secretagogue may be released by an additional unrelated pancreatic endocrine tumor after removal of the gastrinoma is also unlikely. Although pancreatic endocrine tumors producing acid hypersecretion without hypergastrinemia are described [67] [68] [69] , our patients had no evidence of any tumor on imaging studies despite follow-up of up to 14 years. A third possibility is that because many of these patients remained on gastric antisecretory drugs, the post curative acid hypersecretion noted could be due to an exaggerated rebound hypersecretion following withdrawal. Several of our findings make this an unlikely explanation. The mechanism of druginduced rebound is induced hypergastrinemia secondary to profound acid inhibition [11, [20] [21] [22] 57] . This did not occur in our patient's post curative resection, because both while PPI proton pump inhibitors Secretory groups are as defined in Table 1 legend a Acid secretion one hour prior to next dose of antisecretory drug for patients taking antisecretory drugs (n = 40)
b Definitions as outlined in [50] , with drug-induced achlorhydria requiring no acid detected at any follow-up on drug and sustained hypochlorhydria requiring acid secretion reduced to \0.2 mEq/h in [50% of follow-ups c Antisecretory drug dosage was attempted to be reduced in all patients postoperatively as described in methods with the aim if possible to remove all antisecretory drug d Number and percent are as defined in Table 1 legend Results are from the 44 patients without previous acid-reducing surgery taking the antisecretory drugs, as well as when not taking them, fasting gastrin levels remained normal. Furthermore, none of the hypersecretory patients had profound acid suppression due to the careful reduction of drug dosage. In addition, one-half were evaluated after 6-months of taking either no antisecretory drug or only a low dose of H2-antagonist, which, in the literature, are reported to have either no rebound or at most, mild and transient rebound [11, 21, 70] ; and this had no effect on the presence of the hypersecretion. Finally, the magnitude of the acid hypersecretion in our study is much higher than that reported in the published studies of post-antisecretory drug rebound acid hypersecretion. A fourth possible explanation could be proposed that it involves similar mechanisms to that causing idiopathic hypersecretion in patients without ZES. It has been proposed that increased vagal tone is an important contributory factor in patients with idiopathic hypersecretion [71] . However, post curative resection hypersecretion was still seen in 80% (7/9) of our patients with vagotomy post curative resection showing other factors besides vagal tone were contributory to this acid hypersecretion. Furthermore, in almost one half of the patients with postoperative hypersecretion, the magnitude of the hypersecretion was greater than that found in [95% of patients with idiopathic hypersecretion [49] . A final possible explanation for the gastric acid hypersecretion post curative resection could involve persistent ECL and/or parietal cell hyperplasia could be present, which could be contributory to the continuing gastric acid hypersecretion.
As noted above in short-term studies in animals and humans, results show that the drug-induced hypergastrinemia causes ECL and parietal cell hyperplasia/hypertrophy, which can cause rebound hypersecretion following antisecretory treatment and withdrawal. It has been proposed that this increased ECL mass and/or activity, in addition to increased parietal cell mass [22] , which likely contributed to the rebound hypersecretion in these patients treated with PPIs. In patients with the Zollinger-Ellison syndrome, the long-standing hypergastrinemia results in marked ECL-cell hyperplasia [5, 6, 11, 24] and parietal cell hyperplasia/ hypertrophy [72] . A possible explanation for the persisting hypersecretion is that contrary to what the short-term studies show, after prolonged hypergastrinemia of several years duration, these ECL and/or parietal cell changes may not be completely reversible. Alternatively, there may be a functional alteration in these cells such that despite a normal ECL and parietal cell mass, acid hypersecretion persists. Our results provide some support for the former possibility. We found increased parietal cell mass and/or ECL-cell mass were being maintained in the extreme hypersecretors post curative resection. There was a significantly higher frequency of advanced ECL-cell changes in hypersecretors, a significantly higher serum CGA level in extreme hypersecretors, and a significantly higher proportion of hypersecretors with 24-h urinary N-MIAA excretion of [150 mcg/g creatinine. Both of the latter measurements have been shown to reflect the extent of ECL-cell hyperplasia in various studies [30] [31] [32] 34] . What remains unclear from our study is the mechanism causing the continued ECL/parietal cell hyperplasia post curative gastrinoma resection in our patients for a mean of 7 years after reversal of the hypergastrinemia. In all short-term animal and human studies of persistent hypergastrinemia [64] [65] [66] , these parameters return to normal in a few months. To explain our results one has to postulate that either very prolonged hypergastrinemia can trigger mechanisms that cause irreversible changes in ECL/parietal cell hyperplasia, or changes that can be maintained subsequently by normal levels of gastrin. These mechanisms are at present completely unknown. Whether such changes will occur in patients with idiopathic GERD or peptic ulcer disease treated for prolonged periods of time with PPIs, at present, are unknown.
